SEC Filing Summary: Cerecor Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cerecor Inc. on July 20, 2016. The filing discloses a material event regarding a research and development grant award received from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a one-time grant award of $1.0 million intended to fund the development of the company's candidate drug, CERC-501, for the treatment of alcohol use disorder.
Material Changes
There are no comparative financial changes versus a prior period as this is a current event report. The material change is the receipt of the $1.0 million grant, which provides additional resources for the company's research and development pipeline.
Outlook, Risks, and Management Commentary
Management commentary indicates that the grant will support the progression of CERC-501 development. The filing includes a press release (Exhibit 99.1) detailing the award. No specific risks, contingencies, or forward-looking guidance regarding financial performance are detailed in this specific 8-K text beyond the context of the grant utilization.
Investor Verification Checklist
- Verify the terms and conditions of the $1.0 million NIAAA grant, including any milestones or reporting requirements.
- Review the attached press release (Exhibit 99.1) for further details on the CERC-501 development timeline.
- Consult the company's most recent 10-K or 10-Q filings for comprehensive financial health, cash runway, and debt obligations, as this 8-K does not contain such data.